- Home
- HFBL vs KLRS Comparison
HFBL vs KLRS Comparison
Compare HFBL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- KLRS
- Stock Information
- Founded
- HFBL 1924
- KLRS 2019
- Country
- HFBL United States
- KLRS United States
- Employees
- HFBL N/A
- KLRS N/A
- Industry
- HFBL Savings Institutions
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HFBL Finance
- KLRS Health Care
- Exchange
- HFBL Nasdaq
- KLRS Nasdaq
- Market Cap
- HFBL 41.6M
- KLRS 46.0M
- IPO Year
- HFBL N/A
- KLRS N/A
- Fundamental
- Price
- HFBL $13.80
- KLRS $6.64
- Analyst Decision
- HFBL
- KLRS Strong Buy
- Analyst Count
- HFBL 0
- KLRS 2
- Target Price
- HFBL N/A
- KLRS $23.00
- AVG Volume (30 Days)
- HFBL 1.7K
- KLRS 200.4K
- Earning Date
- HFBL 10-28-2025
- KLRS 11-15-2025
- Dividend Yield
- HFBL 3.88%
- KLRS N/A
- EPS Growth
- HFBL 6.78
- KLRS N/A
- EPS
- HFBL 1.26
- KLRS N/A
- Revenue
- HFBL $20,802,000.00
- KLRS N/A
- Revenue This Year
- HFBL N/A
- KLRS N/A
- Revenue Next Year
- HFBL N/A
- KLRS N/A
- P/E Ratio
- HFBL $11.03
- KLRS N/A
- Revenue Growth
- HFBL 1.50
- KLRS N/A
- 52 Week Low
- HFBL $11.75
- KLRS $2.14
- 52 Week High
- HFBL $14.25
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- HFBL 59.85
- KLRS 67.52
- Support Level
- HFBL $13.45
- KLRS $4.41
- Resistance Level
- HFBL $13.73
- KLRS $7.62
- Average True Range (ATR)
- HFBL 0.06
- KLRS 0.81
- MACD
- HFBL 0.01
- KLRS 0.18
- Stochastic Oscillator
- HFBL 100.00
- KLRS 74.68
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.